MESNEX Drug Patent Profile

✉ Email this page to a colleague

When do Mesnex patents expire, and what generic alternatives are available?

Mesnex is a drug marketed by Baxter Hlthcare and is included in two NDAs.

The generic ingredient in MESNEX is mesna. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the mesna profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mesnex

A generic version of MESNEX was approved as mesna by FRESENIUS KABI USA on April 26^th, 2001.

Try a Trial

Summary for MESNEX

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	120
Clinical Trials:	89
Patent Applications:	1,250
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for MESNEX
What excipients (inactive ingredients) are in MESNEX?	MESNEX excipients list
DailyMed Link:	MESNEX at DailyMed

Drug patent expirations by year for MESNEX

Recent Clinical Trials for MESNEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ossium Health, Inc.	Phase 1/Phase 2
Center for International Blood and Marrow Transplant Research	Phase 1/Phase 2
Center for International Blood and Marrow Transplant Research	Phase 1

See all MESNEX clinical trials

Pharmacology for MESNEX

Drug Class	Cytoprotective Agent

Anatomical Therapeutic Chemical (ATC) Classes for MESNEX

R05CB	Mucolytics
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

V03AF	Detoxifying agents for antineoplastic treatment
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

US Patents and Regulatory Information for MESNEX

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	MESNEX	mesna	INJECTABLE;INTRAVENOUS	019884-001	Dec 30, 1988	AP	RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Baxter Hlthcare	MESNEX	mesna	TABLET;ORAL	020855-001	Mar 21, 2002		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for MESNEX

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	MESNEX	mesna	TABLET;ORAL	020855-001	Mar 21, 2002	⤷ Try a Trial	⤷ Try a Trial
Baxter Hlthcare	MESNEX	mesna	TABLET;ORAL	020855-001	Mar 21, 2002	⤷ Try a Trial	⤷ Try a Trial
Baxter Hlthcare	MESNEX	mesna	INJECTABLE;INTRAVENOUS	019884-001	Dec 30, 1988	⤷ Try a Trial	⤷ Try a Trial
Baxter Hlthcare	MESNEX	mesna	INJECTABLE;INTRAVENOUS	019884-001	Dec 30, 1988	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for MESNEX

See the table below for patents covering MESNEX around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Japan	S54101432	DETOXICATION OF CELL PROPAGATION CONTROLLING AGENT	⤷ Try a Trial
Ireland	47609	PROCESS FOR PRODUCING DETOXIFIED PHARMACEUTICAL PRODUCTS CONTAINING A CYTOSTATICALLY ACTIVE ALKYLATING AGENT	⤷ Try a Trial
Finland	97949		⤷ Try a Trial
European Patent Office	0002495	COMPOSITION FOR USE IN CYTOSTATIC THERAPY	⤷ Try a Trial
Latvia	10040	TABLETS, METHOD OF THEIR PREPARATION, GRANULATES AND METHOD OF THEIR PREPARATION	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for MESNEX

Recent Clinical Trials for MESNEX

Pharmacology for MESNEX

Anatomical Therapeutic Chemical (ATC) Classes for MESNEX

Make Better Decisions: Try a trial or see plans & pricing